retatrutide clinical trials latest Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Retatrutide Phase 3: TRIUMPH Program

Oral therapies and off patent semaglutide will affect pricing and access, competition intensifies in an increasingly segmented market, and innovation shifts the focus beyond weight loss alone towards comorbidity benefit, long-term maintenance and muscle preservation

As additional FDA submissions and real-world studies emerge, further clarification of optimal dosing strategies and sustained efficacy will shape its role in future metabolic treatment protocols

Thousands of lawsuits have been filed by Ozempic patients who have experienced a range of complications, including blindness

This article describes the medicinal chemistry optimization and early preclinical evaluation of cagrilintide

I think the primary reason, if not the most significant reason, is creating a barrier for pharmacies to compound this medication if it goes into a shortage situation, Boesen said

The earliest expected NDA filing with the FDA is Q4 2026, which would put a realistic FDA decision in 2027 or later